Faculty

Research

Systems

Infrastructure

Patient & Public Awareness

Working with Industry

Research Databases

About Us

News: NIHR BRCs collaborate to answer questions about best treatment for diffuse large B-cell lymphoma

Title

NIHR BRCs collaborate to answer questions about best treatment for diffuse large B-cell lymphoma 

News Title

NIHR BRCs collaborate to answer questions about best treatment for diffuse large B-cell lymphoma 

News Content

A large multicentre trial designed by researchers at the NIHR Royal Marsden Biomedical Research Centre (BRC) and the NIHR University College London Hospitals BRC, has provided answers to a hotly debated issue concerning the treatment of aggressive diffuse large B Cell Lymphomas (DLBCL). The large randomised study compared CHOP-14 (given every 14 days) with CHOP-21 (given every 21 days) in patients receiving rituximab for 6-8 cycles. In this phase 3 trial, over a three-year period 1,080 patients over 18 years old were randomly assigned the  two different treatment regimens and the primary outcome measure was overall survival. Results showed that those who received more frequent cycles of R-CHOP (every two weeks) did not benefit any more than those receiving a cycle every three weeks.

News Link

NIHR UCL Hospitals BRC 

News Date

28/05/2013 

Expires

05/07/2013 

Date Created

 

Date Modified

 
Attachments
Created at 06/06/2013 16:36  by Leonilde Yahyaoui 
Last modified at 06/06/2013 16:36  by Leonilde Yahyaoui